Presentation made by Zsuzsanna Jakab, WHO Regional Director for Europe, at the meeting "Health in Action reforming the Greek National Health System to Improve Citizens’ Health", on 5 March 2014, Athens, Greece.
Module 1.1 An overview of emerging and re emerging infectious diseasesAdaora Anyichie - Odis
This module helps to understand the global trends of emerging & re-emerging infections and chronic diseases, identify the threats of diseases and develop desirable attitude and skill in planning to go for new treatment regimens and public health programs that substantially reduce and even prevent the spread of infections and promotion of public health
Module 1.1 An overview of emerging and re emerging infectious diseasesAdaora Anyichie - Odis
This module helps to understand the global trends of emerging & re-emerging infections and chronic diseases, identify the threats of diseases and develop desirable attitude and skill in planning to go for new treatment regimens and public health programs that substantially reduce and even prevent the spread of infections and promotion of public health
Presented by Hung Nguyen-Viet and Jakob Zinsstag at a technical workshop of the Food and Agriculture Organization of the United Nations (FAO) regional initiative on One Health, Bangkok, Thailand, 11–13 October 2017.
My Guest Lecture at Mahamicron 2014 - XX Maharashtra Chapter Conference of the Indian Association of Medical Microbiologists, Nagpur, 19/09/2014 to 21/09/2014.
Dr Rajesh Karyakarte Delivered this Guest Lecture on 21/09/2014 at 9:30 AM.
Presented by Habibur Rahman and Vijayalakshmy Kennady (ILRI) at the Strategy Workshop on Foodborne Diseases, National Academy of Agricultural Sciences, New Delhi, India, 21 November 2019
Tropical diseases are the diseases that are most prevalent in tropical regions of the world. There are around 14 tropical diseases that causes great morbidity but still ranks low in the international health agendas and being "neglected" since it is confined to certain regions and does not spread across the globe. These diseases are eliminated in developed countries but are prevalent in developing countries because of improper sanitation.Here,I hope I have covered almost all the neglected tropical diseases.
Emerging and re-emerging diseses part2 (INCLUDES ANTIMICROBIAL RESISTANCE)Dr. Mamta Gehlawat
2nd half of my ppt on emerging and re-emerging diseases. i uploaded the first half already. pls refer to that too. this ppt has info on AIDS/HIV, ZIKA, EBOLA-MARBURG, MELIODIOSIS, CHOLERA and ANTIMICROBIAL RESISTANCE
Emerging and Re-emerging Infectious DiseasesFarooq Khan
Overview of literature around the following emerging and re-emerging infectious diseases relevant to Canadian Emergency Physicians in terms of their epidemiology, recognition, and treatment:
- Community-acquired MRSA
- Non-vaccine serotype Pneumococcus
- Fusobacterium Necrophorum
Neglected tropical diseases in India (NTDs) are a group of bacterial, parasitic, viral, and fungal infections that are common in low income countries but receive little funding to address them. Neglected tropical diseases are common in India.
Presented by Hung Nguyen-Viet and Jakob Zinsstag at a technical workshop of the Food and Agriculture Organization of the United Nations (FAO) regional initiative on One Health, Bangkok, Thailand, 11–13 October 2017.
My Guest Lecture at Mahamicron 2014 - XX Maharashtra Chapter Conference of the Indian Association of Medical Microbiologists, Nagpur, 19/09/2014 to 21/09/2014.
Dr Rajesh Karyakarte Delivered this Guest Lecture on 21/09/2014 at 9:30 AM.
Presented by Habibur Rahman and Vijayalakshmy Kennady (ILRI) at the Strategy Workshop on Foodborne Diseases, National Academy of Agricultural Sciences, New Delhi, India, 21 November 2019
Tropical diseases are the diseases that are most prevalent in tropical regions of the world. There are around 14 tropical diseases that causes great morbidity but still ranks low in the international health agendas and being "neglected" since it is confined to certain regions and does not spread across the globe. These diseases are eliminated in developed countries but are prevalent in developing countries because of improper sanitation.Here,I hope I have covered almost all the neglected tropical diseases.
Emerging and re-emerging diseses part2 (INCLUDES ANTIMICROBIAL RESISTANCE)Dr. Mamta Gehlawat
2nd half of my ppt on emerging and re-emerging diseases. i uploaded the first half already. pls refer to that too. this ppt has info on AIDS/HIV, ZIKA, EBOLA-MARBURG, MELIODIOSIS, CHOLERA and ANTIMICROBIAL RESISTANCE
Emerging and Re-emerging Infectious DiseasesFarooq Khan
Overview of literature around the following emerging and re-emerging infectious diseases relevant to Canadian Emergency Physicians in terms of their epidemiology, recognition, and treatment:
- Community-acquired MRSA
- Non-vaccine serotype Pneumococcus
- Fusobacterium Necrophorum
Neglected tropical diseases in India (NTDs) are a group of bacterial, parasitic, viral, and fungal infections that are common in low income countries but receive little funding to address them. Neglected tropical diseases are common in India.
This presentation is part of the report presented by the WHO Regional Director Zsuzsanna Jakab at the 63rd session of the WHO Regional Committee for Europe in Çeşme Izmir, Turkey, on 16 September 2013.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Speech by: Alexis Goosdeel, EMCDDA Director (European Monitoring Centre for Drugs and Drug Addiction)
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Masoud Dara, WHO Regional Office for Europe
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: John F. Ryan, Director, European Commission, DG SANTE
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the 7th Meeting of the European Advisory Committee on Health Research (Copenhagen, Denmark, 6 April 2016)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Reported measles cases for the period November 2020—October 2021 (data as of 02 December 2021).A monthly summary of the epidemiological data on selected vaccine-preventable diseases in the WHO European Region
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
3. Tuberculosis (TB) incidence (per 100 000 population) and case
detection and treatment success rates (percentage), WHO European
Region, 1990–2010
4. WHO addresses antimicrobial resistance in the
European Region
WHO European action plan, adopted by all 53 Member States,
recognizes that:
– antimicrobial resistance (AMR) is neglected in many
countries of the Region;
– there is no systematic AMR surveillance in a large
part of the Region ;
– there is a need for intersectoral coordination;
– there is international spread of disease through
travel and trade;
– there is a need to share international standards
and data.
5. Implementation of action plan
Specific focus on supporting non-European Union (EU)
Member States in:
• intersectoral coordination (including One Health);
• developing national action plans;
• surveillance of antibiotic consumption
and resistance; and
• awareness raising (including European Antimicrobial Awareness Day).
For example, through country assessments, national and subregional workshops,
training, twinning and consultancies
6. Progress of CAESAR network
(Central Asian and eastern European Surveillance of Antimicrobial Resistance)
– Network of national surveillance networks
– Compatible with EU surveillance
– In close collaboration with the
European Centre for Disease
Prevention and Control (ECDC)
Status:
– 12 countries engaged in activities
– 4 countries submit data to WHO
7. WHO collects Region-wide data on antimicrobial use
• Technical support to analyze consumption data
• Compatible with EU surveillance
• In close collaboration with ECDC
• Status:
– Lancet paper with data
from 13 countries/regions
– Countries follow up with
action
8. Measles cases
Measles incidence in the WHO Region 2004-2011
2004
2005
2006
2007
Month and year
2008
2009
2010
2011
Data Source: Monthly Measles Rubella Surveillance data, CDS/WHO/EURO
Data as of 1 Dec 2011
9. Expansion of influenza surveillance from EU and
European Economic Area countries to all 53 WHO
European Member States
Before expansion
Source: WHO/ Euroflu
10. Health implication of migration:
why important for the health sector?
• In a globalized world defined by profound
disparities, skill shortages, demographic
imbalances and climate change, as well as
economic and political crises and natural and
man-made disasters, migration is omnipresent
• Migration is also essential to compensating
demographic trends and skill shortages and to
assist home communities
11. The WHO European Region and migration
53 Member States; 886 million people
In the WHO European Region
migrants represent 36% of the
population: 77 million migrants
Six of the top 10 countries in the
world with most immigrants are in the
WHO European Region
High level of diversity in gross domestic
product (GDP)/person/year (2009)
–
Tajikistan: US$1900 [rank 192]
–
Luxembourg: US$79 600 [rank 3]
13. Mandate, opportunities and legitimacy of action: WHO
Constitution and World Health Assembly resolutions
2008: World Health Assembly resolution WHA61.17 on the health of migrants
pertains to migrant-sensitive health policies; equitable access to services;
information systems to assess migrant health; best practices; building the
capacity of health-service providers and professionals; intersectoral action
2009: World Health Assembly resolution WHA62.14 on reducing health inequities
through action on the social determinants of health
notes the recommendations of the Commission on Social Determinants of
Health
2010: World Health Assembly resolution WHA63.15 on monitoring the
achievement of the health-related Millennium Development Goals (MDGs)
focuses on protecting the health of the most vulnerable by constantly
monitoring progress towards achievement of the health-related MDGs
2010: global consultation on migrant health, Madrid, Spain
took stock of actions by Member States and stakeholders; reached
consensus on priority areas and strategies; initiates an operational
framework
14. WHO project on the public health aspects of migration
WHO and the National Operational Centre of the Ministry of Health of
Greece are preparing to assess the health sector’s capacity to manage a
large influx of migrants.
Areas of technical collaboration:
•
health-system capacity for emergency preparedness and risk management in
case of a large influx of migrants
•
surveillance of communicable and noncommunicable diseases among migrant
populations during crises
•
equitable access to health services for migrants
•
strengthening the health information system
15. In May 2005, the Fifty-eighth World Health
Assembly adopted the revised International
Health Regulations
To prevent, protect against, control and provide a public health
response to the international spread of disease in ways that
are commensurate with and restricted to public health risks,
and which avoid unnecessary interference with international
traffic.
16. People living with HIV: numbers fast growing in
eastern Europe and central Asia
Estimated number of people living with HIV in Europe, 1990-2011
2.6
Estimated number of people living with HIV (millions)
2.4
2.2
Europe (total estimated)
2.4 million
2.0
[2.1– 2.7 million]
1.8
Eastern Europe and
central Asia
1.5 million
1.6
1.4
[1.3–1.8 million]
1.2
0.8
Western and central
Europe
860 000
0.6
[780 000–960 000]
1.0
0.4
0.2
0.0
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Source Global report: UNAIDS report on the global AIDS epidemic 2012. Geneva:
Joint United Nations Programme on HIV/AIDS (UNAIDS); 2012,
18. HIV infections reported in Greece transmission
group 2006-2011
MSM: men who
have sex with
men
Source: Ministry of Health and Social Solidarity, Hellenic Centre for Disease Control & Prevention (KEELPNO). HIV/AIDS surveillance in Greece.
Thessaloniki: KEELPNO; 2011.
19. HIV prevalence in new injectors Athens
IDUs injecting 2 years or less a proxy for incidence
1 543
2011
20. HIV prevalence in new injectors, Athens
IDUs, 2 years or less: proxy for incidence
1 543
2011
21. Four strategic directions of the European action
plan for HIV/AIDS 2012-2015
Optimize HIV
prevention, dia
gnosis, treatme
nt and care
outcomes
Leverage
broader health
outcomes
through HIV
response
Build strong
and
sustainable
systems
Reduce
vulnerability
and address
structural
barriers to
accessing
services
25. Health systems and the right policies go
hand in hand
2010
2011
2012
2013
26. What is Health 2020?
Health 2020 is a valuebased, action-oriented policy
framework, adaptable to
different realities in the countries
of the WHO European Region.
Health 2020 is addressed to
ministries of health but also aims
to engage ministers and policymakers across government and
stakeholders throughout society
who can contribute to health and
well-being.